CoChat
Sign Up
Cited by 1,617HIV/AIDS Research and InterventionsHIV-related health complications and treatmentsHIV Research and Treatment

. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

Open access
Kuller, Lewis H, Tracy, Russell, Belloso, Waldo, Wit, Stephane De, Drummond, Fraser, Lane, H. Clifford, Ledergerber, Bruno, Lundgren, Jens +5 more·2008·PLoS Medicine
DOI 10.1371/journal.pmed.0050203PMC PMC2570418
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: In the Strategies for Management of Anti-Retroviral Therapy trial, all-cause mortality was higher for participants randomized to intermittent, CD4-guided antiretroviral treatment (ART) (drug conservation [DC]) than continuous ART (viral suppression [VS]).We hypothesized that increased HIV-RNA levels following ART interruption induced activation of tissue factor pathways, thrombosis, and fibrinolysis. METHODS AND FINDINGS: Stored samples were used to measure six biomarkers: high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), amyloid A, amyloid P, D-dimer, and prothrombin fragment 1+2. Two studies were conducted: (1) a nested case-control study for studying biomarker associations with mortality, and (2) a study to compare DC and VS participants for biomarker changes. For (1), markers were determined at study entry and before death (latest level) for 85 deaths and for two controls (n = 170) matched on country, age, sex, and date of randomization. Odds ratios (ORs) were estimated with logistic regression. For each biomarker, each of the three upper quartiles was compared to the lowest quartile. For (2), the biomarkers were assessed for 249 DC and 250 VS participants at study entry and 1 mo following randomization. Higher levels of hsCRP, IL-6, and D-dimer at study entry were significantly associated with an increased risk of all-cause mortality. Unadjusted ORs (highest versus lowest quartile) were 2.0 (95% confidence interval [CI], 1.0-4.1; p = 0.05), 8.3 (95% CI, 3.3-20.8; p < 0.0001), and 12.4 (95% CI, 4.2-37.0; p < 0.0001), respectively. Associations were significant after adjustment, when the DC and VS groups were analyzed separately, and when latest levels were assessed. IL-6 and D-dimer increased at 1 mo by 30% and 16% in the DC group and by 0% and 5% in the VS group (p < 0.0001 for treatment difference for both biomarkers); increases in the DC group were related to HIV-RNA levels at 1 mo (p < 0.0001). In an expanded case-control analysis (four controls per case), the OR (DC/VS) for mortality was reduced from 1.8 (95% CI, 1.1-3.1; p = 0.02) to 1.5 (95% CI, 0.8-2.8) and 1.4 (95% CI, 0.8-2.5) after adjustment for latest levels of IL-6 and D-dimer, respectively. CONCLUSIONS: IL-6 and D-dimer were strongly related to all-cause mortality. Interrupting ART may further increase the risk of death by raising IL-6 and D-dimer levels. Therapies that reduce the inflammatory response to HIV and decrease IL-6 and D-dimer levels may warrant investigation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0050203

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the SMART studies, the fully adjusted odds ratios of mortality (fourth versus first quartile) in HIV disease were 8.0, 12.4, and 41.2 for sCD14, IL-6, and D-dimer, respectively, and these odds ratios are higher than those observed in the general population.

    “For example, in the SMART studies, the fully adjusted odds ratios of mortality (fourth versus first quartile; IQR) in HIV disease were 8.0, 12.4, and 41.2 for sCD14, IL-6 and D-dimer, respectively (47); these odds ratios are higher than those observed in the general population.”

    From HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group (2012) · cites this paper as [47]

  • The mechanisms accounting for the excess risk of HANA conditions in long-term treated HIV-infected adults likely include persistent immune dysfunction/inflammation, treatment toxicity, co-infections such as CMV, HCV, and HBV, and traditional risk factors including use of alcohol, tobacco, and psychoactive drugs.

    “The mechanisms accounting for this excess risk likely include persistent immune dysfunction/inflammation, treatment toxicity, co-infections such as CMV, HCV and hepatitis B virus (HBV) and traditional risk factors (including use of alcohol, tobacco, and psychoactive drugs) (15,47,48).”

    From HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group (2012) · cites this paper as [47]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 42 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Kuller, L. H., Tracy, R., Belloso, W., Wit, S. D., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J., Neuhaus, J., Nixon, D., Paton, N. I., Neaton, J. D., & for the INSIGHT SMART Study Group
Affiliations
  • University of Pittsburgh (US)
  • University of Vermont (US)
  • Hospital Italiano de Buenos Aires (AR)
  • UNSW Sydney (AU)
  • National Institutes of Health (US)
  • University Hospital Zurich (CH)
  • University of Copenhagen (DK)
  • University of Minnesota (US)
  • Virginia Commonwealth University (US)
  • Medical Research Council (GB)
Corresponding author
Neaton, James D
ORCID
Venue
PLoS Medicine
Publisher
Public Library of Science (PLoS)
Published
2008-10-21
Volume
5
Issue
10
Pages
e203
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
DOI
10.1371/journal.pmed.0050203
PMC
PMC2570418
OpenAlex
W2153136696
Cited by
1,617
References
42
Citations by year
2026: 40 · 2025: 42 · 2024: 57 · 2023: 56 · 2022: 70 · 2021: 77 · 2020: 98 · 2019: 82 · 2018: 105 · 2017: 86 · 2016: 120 · 2015: 129 · 2014: 146 · 2013: 142 · 2012: 118
FWCI
53.14
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS Medicine (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion, cc-by)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, cc-by)
  • National University of Singapore (submittedVersion)
  • VCU Scholars Compass (Virginia Commonwealth University) (submittedVersion, public-domain)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • GlaxoSmithKline
  • Gilead Sciences
  • Wake Forest University
  • Johns Hopkins University
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (U01 AI46362, U01AI046362, U01AI042170)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
HIV infection, all-cause mortality, inflammatory markers, coagulation markers, C-reactive protein, interleukin-6, D-dimer, prothrombin fragment 1+2, amyloid A, antiretroviral therapy interruption, viral rebound, thrombosis, fibrinolysis, tissue factor
MeSH terms
Serum Amyloid P-Component, Serum Amyloid A Protein, Blood Coagulation, C-Reactive Protein, Cause of Death, Female, Fibrin Fibrinogen Degradation Products, Follow-Up Studies, Humans, Inflammation, Male, Multicenter Studies as Topic, Biomarkers, HIV Infections, Interleukin-6, Survival Rate, Logistic Models, Odds Ratio, Case-Control Studies, Randomized Controlled Trials as Topic, Treatment Outcome, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review